Omeros Corp. (OMER)

13.05
0.06 0.46
NASDAQ : Health Technology
Prev Close 13.11
Open 13.22
Day Low/High 12.72 / 13.27
52 Wk Low/High 8.36 / 27.00
Volume 112.53K
Avg Volume 909.80K
Exchange NASDAQ
Shares Outstanding 49.01M
Market Cap 656.23M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Omeros Announces Additions To Senior Management Team

Omeros Announces Additions To Senior Management Team

Omeros Corporation (Nasdaq: OMER) today announced that it hired two new senior management team members - Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.

Omeros Announces Pricing Of $210 Million Offering Of Convertible Senior Notes Due 2023

Omeros Announces Pricing Of $210 Million Offering Of Convertible Senior Notes Due 2023

Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced the pricing of an offering of $210 million aggregate principal amount of its 6.

Omeros Announces Proposed $210 Million Offering Of Convertible Senior Notes Due 2023

Omeros Announces Proposed $210 Million Offering Of Convertible Senior Notes Due 2023

SEATTLE, Nov. 8, 2018 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the...

Omeros Corporation Reports Third Quarter 2018 Financial Results

Omeros Corporation Reports Third Quarter 2018 Financial Results

Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2018, which include: 3Q 2018 total and OMIDRIA ® revenues were $4.

Omeros Corporation To Announce Third Quarter 2018 Financial Results On November 9, 2018

Omeros Corporation To Announce Third Quarter 2018 Financial Results On November 9, 2018

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018, on Friday, November 9, 2018, before the market opens.

Reflecting on 9/11: Cramer's 'Mad Money' Recap (Tuesday 9/11/18)

Reflecting on 9/11: Cramer's 'Mad Money' Recap (Tuesday 9/11/18)

Jim Cramer says he believes we are today better prepared for both the terror and the financial attacks that America endured on 9/11.

Cypress Semiconductor, Omeros, Zuora: 'Mad Money' Lightning Round

Cypress Semiconductor, Omeros, Zuora: 'Mad Money' Lightning Round

Jim Cramer weighs in on Cypress Semiconductor, Omeros, Zuora, Kemet, Leidos, Raytheon, and Skyworks Solutions.

FDA Grants Orphan Drug Designation To Omeros' OMS721 For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

FDA Grants Orphan Drug Designation To Omeros' OMS721 For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Corporation (NASDAQ:OMER) today announced that OMS721 has received orphan drug designation from the U.

Relative Strength Alert For Omeros

Relative Strength Alert For Omeros

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Omeros Corporation Announces Additional Positive Data For OMS721 In IgA Nephropathy

Omeros Corporation Announces Additional Positive Data For OMS721 In IgA Nephropathy

Omeros Corporation (NASDAQ: OMER) today announced positive data from the company's ongoing Phase 2 clinical trial of OMS721 for the treatment of renal diseases.

Omeros Corporation Announces Reinstatement Of Pass-Through Status For OMIDRIA®

Omeros Corporation Announces Reinstatement Of Pass-Through Status For OMIDRIA®

Omeros Corporation (NASDAQ: OMER) announced that reinstatement of separate payment by the Centers for Medicare and Medicaid Services (CMS) under the pass-through program for the company's cataract surgery drug OMIDRIA ® (phenylephrine and ketorolac...

Omeros To Present At The 2018 Cantor Global Healthcare Conference

Omeros To Present At The 2018 Cantor Global Healthcare Conference

Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.

Omeros To Present At The Morgan Stanley Global Healthcare Conference

Omeros To Present At The Morgan Stanley Global Healthcare Conference

Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.

Names to Watch Amid Biotech's Nascent Rally

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.

European Commission Designates OMS721 As An Orphan Medicinal Product For Treatment In Hematopoietic Stem Cell Transplantation

European Commission Designates OMS721 As An Orphan Medicinal Product For Treatment In Hematopoietic Stem Cell Transplantation

Omeros Corporation (Nasdaq: OMER) today announced that the European Commission (EC) has adopted a decision designating OMS721 as an Orphan Medicinal Product in the European Union (EU) for treatment in hematopoietic stem cell transplantation (HSCT).

Notable Friday Option Activity: OMER, SQ, VTL

Notable Friday Option Activity: OMER, SQ, VTL

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Omeros Corp , where a total of 2,615 contracts have traded so far, representing approximately 261,500 underlying shares. That amounts to about 58.2% of OMER's average daily trading volume over the past month of 449,185 shares.

Omeros To Present At The 2018 Wedbush PacGrow Healthcare Conference

Omeros To Present At The 2018 Wedbush PacGrow Healthcare Conference

Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.

Omeros Corporation Reports Second Quarter 2018 Financial Results

Omeros Corporation Reports Second Quarter 2018 Financial Results

Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2018, which include: 2Q 2018 total and OMIDRIA ® revenues were $1.

Omeros Corporation To Announce Second Quarter 2018 Financial Results On August 9, 2018

Omeros Corporation To Announce Second Quarter 2018 Financial Results On August 9, 2018

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2018 financial results for the period ended June 30, 2018, on Thursday, August 9, 2018, after the market closes.

Omeros Hires Former Sanofi Global Development Head As Chief Medical Officer

Omeros Hires Former Sanofi Global Development Head As Chief Medical Officer

Omeros Corporation (Nasdaq: OMER) today announced that Eckhard Leifke, M.D.

Sandoz Amends ANDA To Not Seek Approval For Generic Version Of OMIDRIA Until Patents For Omeros' Drug Expire

Sandoz Amends ANDA To Not Seek Approval For Generic Version Of OMIDRIA Until Patents For Omeros' Drug Expire

Omeros Corporation (Nasdaq: OMER) today announced that its patent infringement lawsuit against Sandoz Inc.

Interesting OMER Put And Call Options For February 2019

Interesting OMER Put And Call Options For February 2019

Investors in Omeros Corp saw new options begin trading this week, for the February 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 205 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Omeros' OMS721 Receives European Orphan Drug Designation Positive Opinion For Treatment In Hematopoietic Stem Cell Transplantation

Omeros' OMS721 Receives European Orphan Drug Designation Positive Opinion For Treatment In Hematopoietic Stem Cell Transplantation

Omeros Corporation (Nasdaq: OMER) announced today that the European Medicines Agency's (EMA's) Committee for Orphan Medicinal Products (COMP) issued a positive opinion recommending orphan drug designation of OMS721 for treatment in hematopoietic stem cell...

Omeros Corporation Initiates Sales Of OMIDRIA® In Europe

Omeros Corporation Initiates Sales Of OMIDRIA® In Europe

Omeros Corporation (NASDAQ: OMER) today announced initial sales of OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1%/0.

Omeros Initiates Dosing In Phase 1 Clinical Trial For OMS527 Targeting Addiction

Omeros Initiates Dosing In Phase 1 Clinical Trial For OMS527 Targeting Addiction

Omeros Corporation (NASDAQ: OMER) today announced that the first cohort of subjects has been dosed in the Company's Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in Omeros' OMS527 program broadly targeting addictions and...

Omeros Obtains Approval To Initiate Phase 1 Clinical Trial For Its OMS527 Addiction Treatment

Omeros Obtains Approval To Initiate Phase 1 Clinical Trial For Its OMS527 Addiction Treatment

Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory authority and ethics committee clearance to start the Phase 1 clinical trial evaluating its lead phosphodiesterase 7 (PDE7) inhibitor from the company's OMS527 program.

Omeros Announces Settlement Of Infringement Suit Against ANDA Filer Lupin

Omeros Announces Settlement Of Infringement Suit Against ANDA Filer Lupin

Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a settlement agreement with Lupin Ltd.

Interesting OMER Put And Call Options For July 20th

Investors in Omeros Corp saw new options become available this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OMER options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: D- (Sell)